

June 2, 2020

Denka Company Limited

Commencement of Shipment of Diethyl Malonate, Raw Materials for “Avigan”

Denka Company Limited (headquarters: Chuo-ku, Tokyo; president: Manabu Yamamoto; hereinafter “Denka”) is pleased to announce that Denka has commenced shipping diethyl malonate, a raw material used to produce the anti-flu medicine Avigan® Tablet (generic name: Favipiravir; “Avigan” hereinafter) that is administered to patients with the COVID-19 coronavirus (“COVID-19,” hereinafter), at the Omi Plant in Itoigawa, Niigata Prefecture, since June 1, 2020.

Denka, as a raw material manufacturer, will supply it quickly to achieve stockpiles of Avigan for two million patients, which the Japanese government has determined as an urgent economic policy. Denka will also aim for the mass-production of rapid test kits as soon as possible for preventing the spread of COVID-19, an urgent global issue, to fulfill its social responsibilities.

*Avigan is a registered trade name of FUJIFILM Toyama Chemical Co., Ltd.

For reference:

Notice Concerning the Supply of Raw Materials for “Avigan,” dated April 2, 2020

https://www.denka.co.jp/eng/storage/news/pdf/274/20200402_denka_supply_dem_en.pdf

Commencement of Production of Diethyl Malonate, Raw Materials for “Avigan,” dated May 13, 2020

https://www.denka.co.jp/eng/storage/news/pdf/280/20200513_denka_supply_dem_en.pdf

About Denka: Denka is a chemical manufacturer headquartered in Chuo-ku, Tokyo. The company specializes in developing business activities on a global scale across a wide range of fields, from inorganic and organic chemicals, to electronic materials and pharmaceuticals. Founded in 1915, Denka has steadily continued to develop and manufacture products that contribute to the development of society by fully utilizing its unique concepts and technological capabilities. Upholding its corporate slogan, “Possibility of Chemistry,” the company and its president, Manabu Yamamoto, are committed to contributing to the sound development of society while sincerely tackling the challenges that society is now confronting.

[For Inquiries about This Press Release from Media]

Corporate Communications Dept. Tel : +81-3-5290-5511